Novartis announced results of a retrospective, real-world evidence study in patients with immune thrombocytopenia (ITP) treated with Promacta® (eltrombopag), compared to other second-line...

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that the...

Petra Pharma Corporation, a drug development company focused on novel therapies that modulate phosphoinositide (PI) signaling pathways, today presented preclinical data in an oral presentation at...

Novartis today announced longer-term analyses of both ELIANA and JULIET, the pivotal clinical trials of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory...

RogCon Biosciences (RogCon), a biotechnology company focused on discovering and developing novel therapeutics for children suffering from SCN2A mutations, today announced preclinical data in a...